Patten Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Patten Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-17	Closed	-$1K	–	232
2018 Q4	$1K	Buy	+17	New	+$1.62K	﹤0.01%	557

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Patten Group's BMRN Position: Q1 2019 in Review

Patten Group sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2019, closing a stake of 17 shares — an estimated $1K sold.

Patten Group first reported a position in BMRN in Q4 2018 and held it in 1 quarter. The position peaked at $1K in Q4 2018. 486 funds tracked by Wall St. Rank hold BMRN as of Q1 2019.

Patten Group reported no remaining BioMarin Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Patten Group sold 17 BioMarin Pharmaceuticals shares in Q1 2019, an estimated $1K.
Patten Group first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 1 quarter.
Patten Group's BioMarin Pharmaceuticals position peaked at $1K in Q4 2018.
486 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2019.

Based on Patten Group's 13F filing for Q1 2019, filed 14 May 2019.